Evidence map›Paper›PMID 17241873›Full record

ArticleGastroenterology2007

5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint.

M Gloria Luciani, Christoph Campregher, John M Fortune, Thomas A Kunkel, Christoph Gasche

Open access · bronzeAbstract read
In one paragraph

Article in Gastroenterology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 77 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Chemoprevention of colorectal cancer.Digestive diseases (Basel, Switzerland) · 2015
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

M Gloria LucianiMedical University of Vienna, Department of Internal Medicine IV, Division of Gastroenterology and Hepatology, Währinger Gürtel 18, A-1090 Vienna, Austria.
Christoph Campregher
John M Fortune
Thomas A Kunkel
Christoph Gasche
Medical University of Vienna · ATNational Institute of Environmental Health Sciences · US

Funding

Studies Of DNA Mismatch RepairZIAES065089 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI KUNKEL, THOMAS A · 2009 to 2025
$17.8M
STUDIES OF DNA MISMATCH REPAIRZ01ES065089 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI KUNKEL, THOMAS A · 1997 to 2008
$1.3M
Austrian Science Fund FWF P 18270Intramural NIH HHS
6 · The paper itself

Abstract

BACKGROUND &

aimsIndividuals with inflammatory bowel disease are at risk of developing colorectal cancer (CRC). Epidemiologic, animal, and laboratory studies suggest that 5-amino-salicylic acid (5-ASA) protects from the development of CRC by altering cell cycle progression and by inducing apoptosis. Our previous results indicate that 5-ASA improves replication fidelity in colorectal cells, an effect that is active in reducing mutations. In this study, we hypothesized that 5-ASA restrains cell cycle progression by activating checkpoint pathways in colorectal cell lines, which would prevent tumor development and improve genomic stability.

methodsCRC cells with different genetic backgrounds such as HT29, HCT116, HCT116(p53-/-), HCT116+chr3, and LoVo were treated with 5-ASA for 2-96 hours. Cell cycle progression, phosphorylation, and DNA binding of cell cycle checkpoint proteins were analyzed.

resultsWe found that 5-ASA at concentrations between 10 and 40 mmol/L affects cell cycle progression by inducing cells to accumulate in the S phase. This effect was independent of the hMLH1, hMSH2, and p53 status because it was observed to a similar extent in all cell lines under investigation. Moreover, wash-out experiments demonstrated reversibility within 48 hours. Although p53 did not have a causative role, p53 Ser15 was strongly phosphorylated. Proteins involved in the ATM-and-Rad3-related kinase (ATR)-dependent S-phase checkpoint response (Chk1 and Rad17) were also phosphorylated but not ataxia telengectasia mutated kinase.

conclusionsOur data demonstrate that 5-ASA causes cells to reversibly accumulate in S phase and activate an ATR-dependent checkpoint. The activation of replication checkpoint may slow down DNA replication and improve DNA replication fidelity, which increases the maintenance of genomic stability and counteracts carcinogenesis.

Indexed as

Adaptor Proteins, Signal TransducingAnti-Inflammatory Agents, Non-SteroidalApoptosisAtaxia Telangiectasia Mutated ProteinsCarrier ProteinsCell CycleCell Cycle ProteinsCell DivisionCheckpoint Kinase 1Colorectal NeoplasmsDNA-Binding ProteinsDNA Mismatch RepairDNA Polymerase IIIDNA ReplicationFlow CytometryHT29 CellsAdaptor Proteins, Signal TransducingAnti-Inflammatory Agents, Non-SteroidalAtaxia Telangiectasia Mutated ProteinsATR protein, humanCarrier ProteinsCDC45 protein, humanCell Cycle ProteinsCheckpoint Kinase 1CHEK1 protein, humanCLSPN protein, humanDNA-Binding ProteinsDNA Polymerase IIIMCM2 protein, humanMCM7 protein, humanMesalamineMinichromosome Maintenance Complex Component 2Minichromosome Maintenance Complex Component 7MLH1 protein, humanMutL Protein Homolog 1Nuclear ProteinsProtein KinasesProtein Serine-Threonine KinasesRad17 protein, humanTumor Suppressor Protein p53

Identifiers

PMID17241873
PMCPMC1839818
OpenAlexW2109265894

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.